Beam Therapeutics
BEAM
Performance
About Beam Therapeutics
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using base editing to treat genetic diseases. The company emphasizes clinically validated delivery technologies, including electroporation, nonviral and viral modalities, to advance its base editing programs. With operations in locations such as Cambridge, Massachusetts and Durham, North Carolina, Beam aims to expand the potential of gene-based editing and bring novel therapies to patients through pipelines and clinical trials.
Recent News
Sickle Cell Disease After Casgevy: Seven Companies to Watch in 2026
Keep an Eye on These 15 Biotech Companies in 2026
Gene Editing Has the Science Figured Out and Now Needs an Entire Stack of New Business Models, Reimbursement Mechanics, and Healthcare Operating Infrastructure Before Any of This Scales to Patients
Chinese Trial Backs Base-Editing Drug for Thalassaemia
Eli Lilly Signs $2.25 B AI‑driven DNA‑editing Pact with Profluent Bio
Labiotech’s 15 Biopharma Companies to Watch in 2026
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Gene Editing ‘Promising’ for Sickle Cell Disease
Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Beam One-Ups Wave as Both Show Promise of Editing for AATD